Vaxcell-Bio Therapeutics Logo

Vaxcell-Bio Therapeutics

Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.

323990 | KO

Overview

Corporate Details

ISIN(s):
KR7323990002
LEI:
Country:
South Korea
Address:
전라남도 화순군 화순읍 산단길 12-55, 화순군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of anti-cancer immunotherapies. The company's core R&D is centered on its proprietary Natural Killer (NK) cell and Chimeric Antigen Receptor (CAR) technology platforms, developing advanced CAR-T and CAR-NK cell therapies. Its pipeline targets a range of malignancies, including liver cancer, pancreatic cancer, small cell lung cancer, and other solid tumors. A notable product, Vaxleukin-15, is an approved immunotherapy adjunct for canine lymphoma. The company actively secures intellectual property for its novel methods of manufacturing high-purity immune cells, positioning itself as a key developer in patient-specific cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항 (박스루킨-15주 (Vaxleukin-15 inj) 품목허가 변경신청 승인)
Korean 11.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-28 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.9 KB
2025-06-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 126.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 17.0 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 17.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 19.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 19.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 20.2 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 20.2 KB
2025-04-02 00:00
Regulatory News Service
유형자산취득결정(자율공시)
Korean 8.1 KB
2025-03-28 00:00
M&A Activity
[기재정정]합병등종료보고서(합병)
Korean 32.6 KB

Automate Your Workflow. Get a real-time feed of all Vaxcell-Bio Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vaxcell-Bio Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vaxcell-Bio Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.